AlphaCore Capital LLC Buys 12,423 Shares of Sanofi $SNY

AlphaCore Capital LLC raised its stake in Sanofi (NASDAQ:SNY) by 441.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 15,234 shares of the company’s stock after purchasing an additional 12,423 shares during the period. AlphaCore Capital LLC’s holdings in Sanofi were worth $719,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in SNY. Financial Consulate Inc. bought a new stake in shares of Sanofi during the third quarter valued at approximately $26,000. First Horizon Corp bought a new position in shares of Sanofi in the 3rd quarter worth $33,000. Salomon & Ludwin LLC lifted its holdings in shares of Sanofi by 1,046.3% in the 3rd quarter. Salomon & Ludwin LLC now owns 768 shares of the company’s stock worth $39,000 after purchasing an additional 701 shares in the last quarter. Nisa Investment Advisors LLC grew its position in Sanofi by 233.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,000 shares of the company’s stock valued at $48,000 after purchasing an additional 700 shares during the period. Finally, Traub Capital Management LLC bought a new stake in Sanofi during the 2nd quarter valued at $51,000. Institutional investors own 14.03% of the company’s stock.

Sanofi Trading Up 0.6%

Shares of Sanofi stock opened at $48.66 on Friday. The company’s 50-day moving average price is $47.54 and its 200-day moving average price is $48.58. The company has a current ratio of 1.09, a quick ratio of 0.73 and a debt-to-equity ratio of 0.20. Sanofi has a 12-month low of $44.62 and a 12-month high of $60.12. The company has a market cap of $118.68 billion, a price-to-earnings ratio of 13.52, a PEG ratio of 1.25 and a beta of 0.45.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on SNY shares. Bank of America lowered shares of Sanofi from a “buy” rating to a “neutral” rating in a report on Thursday, February 12th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Sanofi in a report on Friday, January 16th. UBS Group reiterated a “neutral” rating on shares of Sanofi in a report on Friday, January 16th. HSBC reissued a “buy” rating on shares of Sanofi in a research report on Wednesday, December 10th. Finally, Citigroup initiated coverage on shares of Sanofi in a report on Tuesday, January 27th. They set a “neutral” rating on the stock. Five equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $62.67.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.